



## Guidance on an additional dose of COVID-19 vaccines in the spring of 2024 for individuals at high risk of severe illness due to COVID-191

Starting in the spring of 2024, NACI recommends that the following individuals who are at increased risk of severe illness from COVID-19 may receive an additional dose of XBB.1.5 COVID-19 vaccine:

- · Adults 65 years of age and older
- · Adult residents of long-term care homes and other congregate living settings for seniors;
- Individuals 6 months and age and older who are moderately to severely immunocompromised (due to an underlying condition or treatment).

The recommended interval is 6 months from the last COVID-19 vaccine dose. Shorter interval of at least 3 months (i.e., a minimum interval of 3 months) may be used, to support implementation (including timing of the spring campaign relative to previous and future fall campaigns).

\*refer to your provincial health guidelines for more details.

### CONSIDER SPIKEVAX® XBB.1.5 FOR YOUR PATIENTS THIS SPRING

- One Vial for All
  - Moderna's SPIKEVAX® XBB.1.5 COVID-19 vaccine is available in one multidose vial for administration to all eligible individuals, 6 months and up.2
- **New Flexibility** According to the Canadian Immunization Guide (CIG), there is no longer a product preference between COVID-19 mRNA vaccines for individuals 12 to 29 years of age.3
- Helping to protect higher-risk Individuals SPIKEVAX® XBB.1.5 dosing considerations: Individuals ≥ 12 Years of Age: One dose of 50 mcg (0.5mL dose volume). Refer to your provincial spring guidance for high risk individuals.<sup>2</sup>





# DOWNLOAD THE DASH QUICK REFERENCE **GUIDE AT SPIKEVAX.COM**

Consult the Product Monograph at spikevax.com/en-CA/xbb15-pm.pdf for contraindications, warnings and precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling us at 1-866-MODERNA (1-866-663-3762).

- Guidance on an additional dose of COVID-19 vaccines in the spring https://www.canada.ca/en/publichealth/services/publications/vaccinesimmunization/national-advisory-committee-immunization-quidance-additional-dose-covid19-vaccines-spring-2024-individuals-high-risk-severeillness-due-covid-19.html
- 2. SPIKEVAX® XBB.1.5 Product Monograph. Updated September 12, 2023. https://covid-vaccine.canada.ca/info/pdf/spikevaxxbb-1-5-pm-en.pdf
- COVID-19 vaccines: Canadian Immunization Guide https://www.canada.ca/en/public-health/services/publications/healthyliving/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html



